i-PET (Granzyme B imaging)

1AD·Adalta·Immuno-oncology diagnostic PET imaging to detect Granzyme B activity·Preclinical·[ TODO: fill in ]

Plain-language Brief

The trial in plain terms

The disease: In cancer immunotherapy, a key challenge is determining whether a patient's immune system is actively attacking a tumour. Granzyme B is a protein released by immune cells, specifically cytotoxic T lymphocytes and natural killer cells, when they are killing tumour cells. Detecting Granzyme B activity non-invasively could help clinicians assess whether an immune response is occurring in a tumour. No Granzyme B-targeted imaging agent is currently approved for clinical use.
What the asset is trying to do: i-PET uses a radiolabelled i-body, a proprietary small binding protein developed by Adalta, to target Granzyme B in tissue. i-bodies are described by Adalta as approximately one-tenth the size of conventional antibodies, which the company states may allow improved tissue penetration. The radiolabel enables the agent to be detected by positron emission tomography (PET) scanning. This approach differs from standard PET tracers, which typically measure metabolic activity rather than a specific immune-killing signal.

Sources for this brief (3)

Adalta i-PET / GE HealthCare licensing and co-development announcement · Adalta (ASX: 1AD) · accessed 15 June 2026
Granzyme B as an imaging biomarker of immune cell activity: literature review · [ TODO: fill in ] · accessed 15 June 2026
GE HealthCare pipeline disclosures · GE HealthCare

Trial Design

Design summary

Phase: Preclinical
Design type: [ TODO: fill in ]
Primary endpoint: [ TODO: fill in ]
Key secondary endpoints: [ TODO: fill in ]
Enrolment target: [ TODO: fill in ]
Current enrolment status: [ TODO: fill in ]
Sites: [ TODO: fill in ]
Expected readout window: [ TODO: fill in ]

Asset Track Record

Did 1AD deliver against its own guidance?

Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.

1 July 2026partnershipOktopi AI collaboration for research efficiencyhitsrc ASX ↗
15 June 2026regulatory decisionShareholder approval at EGM for options offerhitsrc ASX ↗
24 May 2026regulatory decisionBZDS1901 FDA — Regulatory advisors appointed for BZDS1901hit · positivesrc ASX ↗
24 May 2026otherProspectushitsrc ASX ↗
3 May 2026financing$2.5m placementhitsrc ASX ↗
3 May 2026financingProposed issue of securities - 1ADhitsrc ASX ↗

Class Catalyst Calendar

What's landed, what's next for i-PET (Granzyme B imaging) and peers

i-PET (Granzyme B imaging)'s own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for i-PET (Granzyme B imaging).

ConferenceAACR Annual Meeting 2026· ChicagoApr 2026
ConferenceASCO Annual Meeting 2026· ChicagoMay 2026
Today
ConferenceESMO Congress 2026· Madrid

Trial design comparison

How i-PET (Granzyme B imaging) reads against active peer trials

Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.

Trial	Sponsor	Class	Phase / Line	Design	Primary endpoint	Dosing	Key eligibility	n
i-PET (Granzyme B imaging)	Adalta	Diagnostic Device	Preclinical[ TODO: fill in ]	[ TODO: fill in ]	[ TODO: fill in ]	[ TODO: fill in ]	[ TODO: fill in ]	0
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56	Memorial Sloan Kettering Cancer Center

Competitor Landscape

Competing programmes by mechanism and phase

Read-across commentary attached per trial. Phase ordering preserved within each group.

OtherASX peers ›

1 activeexpand ›

MS
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
PHASE1/PHASE2
Memorial Sloan Kettering Cancer Center·Recruiting·Primary completion 11 June 2026·NCT04199741

Curated Commentary

Third-party coverage(none curated yet)

expand ›

External analyst notes, journalism, and industry commentary cited with attribution.

No third-party coverage curated for i-PET (Granzyme B imaging) yet. Broker coverage of Adalta is thin; named analyst notes will appear here as they become available. For now, see the company's ASX announcements and the linked sponsor / class sources elsewhere on this page.